| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN8 |
| Uniprot No | P56748 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-225aa |
| 氨基酸序列 | MATHALEIAGLFLGGVGMVGTVAVTVMPQWRVSAFIENNIVVFENFWEGLWMNCVRQANIRMQCKIYDSLLALSPDLQAARGLMCAASVMSFLAFMMAILGMKCTRCTGDNEKVKAHILLTAGIIFIITGMVVLIPVSWVANAIIRDFYNSIVNVAQKRELGEALYLGWTTALVLIVGGALFCCVFCCNEKSSSYRYSIPSHRTTQKSYHTGKKSPSVYSRSQYV |
| 分子量 | 51.2 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CLDN8蛋白的虚构参考文献示例(基于学术写作惯例)：
1. **文献名称**：*"Recombinant human CLDN8 suppresses colorectal cancer metastasis by modulating epithelial-mesenchymal transition"*
**作者**：Zhang L, et al.
**摘要**：本研究通过构建重组人CLDN8蛋白，发现其能够通过抑制Wnt/β-catenin信号通路，降低结直肠癌细胞迁移能力，并阻断上皮-间质转化(EMT)，提示CLDN8可能作为结直肠癌治疗的潜在靶点。
2. **文献名称**：*"Expression and purification of recombinant human CLDN8 in a mammalian system: Implications for gut barrier function studies"*
**作者**：Smith KA, et al.
**摘要**：研究成功利用HEK293细胞表达并纯化功能性重组人CLDN8蛋白，证实其通过增强体外肠上皮细胞模型的跨上皮电阻(TEER)，显著改善肠道屏障完整性，为炎症性肠病机制研究提供工具。
3. **文献名称**：*"CLDN8 interacts with ZO-1 in recombinant form: Structural insights into tight junction assembly"*
**作者**：Tanaka H, et al.
**摘要**：通过表面等离子共振(SPR)分析，发现重组人CLDN8蛋白直接结合紧密连接蛋白ZO-1.揭示了CLDN8在维持细胞极性及紧密连接动态组装中的分子机制。
4. **文献名称**：*"Recombinant CLDN8 attenuates bacterial translocation in sepsis via TLR4/NF-κB pathway inhibition"*
**作者**：Wang Y, et al.
**摘要**：动物实验表明，外源性重组CLDN8蛋白可通过抑制TLR4介导的炎症反应，减少脓毒症模型小鼠的肠源性细菌移位，提示其在脓毒症治疗中的潜在应用价值。
---
**注**：以上为基于学术逻辑虚构的参考文献，实际研究中请通过PubMed、Web of Science等平台检索真实文献。
Claudin-8 (CLDN8) is a member of the claudin family, a group of transmembrane proteins essential for forming tight junctions (TJs) that regulate paracellular permeability and maintain cell polarity. Located primarily in epithelial and endothelial tissues, CLDN8 is highly expressed in the colon, kidney, and prostate. It plays a critical role in controlling ion selectivity and barrier function by sealing intercellular spaces. Structurally, CLDN8 contains four transmembrane domains, intracellular N- and C-termini, and extracellular loops critical for homotypic/heterotypic interactions with other claudins.
Dysregulation of CLDN8 is implicated in various pathologies. Reduced expression correlates with compromised intestinal barrier integrity in inflammatory bowel disease (IBD) and colitis-associated cancer, while overexpression in certain cancers may promote tumor progression. Additionally, CLDN8 interacts with pathogens; its downregulation by Helicobacter pylori contributes to gastric epithelial damage.
Recombinant human CLDN8 protein, typically produced in mammalian or bacterial expression systems, retains functional epitopes and structural integrity. It is widely used to study TJ dynamics, screen therapeutic agents targeting epithelial barriers, and develop antibodies for diagnostic or therapeutic applications. Research leveraging recombinant CLDN8 also explores its role in drug delivery modulation and epithelial-mesenchymal transition mechanisms. Its application advances understanding of TJ-related diseases and potential precision therapies.
×
